Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Berg Pharma Stories

2013-11-21 12:27:04

-- Patients at Cornell, the Palo Alto Medical Foundation, MD Anderson Participate in First Clinical Program to Comprehensively Use Artificial Intelligence -- FRAMINGHAM, Mass., Nov. 21, 2013 /PRNewswire/ -- Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach, today announced a first-of-its-kind Phase Ib clinical trial with Weill Cornell Medical College, Palo Alto Medical Foundation, and MD Anderson Cancer...

2013-09-11 12:24:59

Company's Interrogative Biology(TM) Platform Recognized for Breakthrough, Data-Driven Scientific Approach BOSTON, Sept. 11, 2013 /PRNewswire/ -- Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach, was recognized today with the 2013 North American Drug Discovery Technology Innovation Award at the Frost & Sullivan Growth, Innovation and Leadership Awards Gala, the annual event by the global research...

2013-04-06 08:20:12

Data from Berg's Proprietary Interrogative Biology(TM) Platform presented at the AACR Annual Meeting 2013 FRAMINGHAM, MA, April 6, 2013 /PRNewswire/ - Berg - a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach - announced today that it will be presenting four abstracts at the AACR Annual Meeting 2013, in Washington, D.C. These data reveal key insights about cancer-cell metabolism and add to the growing body...

2012-07-23 02:24:53

NEW YORK, July 23, 2012 /PRNewswire/ -- Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled "Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer." The trial will be conducted at Memorial Sloan-Kettering Cancer...

2012-06-25 06:31:29

CAMBRIDGE, Mass. and SUNNYVALE, Calif., June 25, 2012 /PRNewswire/ -- Berg Pharma, a Boston-based pharmaceutical company and the renowned Parkinson's Institute announced a unique partnership that would enable a more robust modeling in the investigation of Parkinson's Disease (PD). There are approximately one million Americans who live with the disease with 50,000 new cases per year and this rate is expected to rise with an aging baby boomer population. The underlying...

2012-06-12 02:25:55

CAMBRIDGE, Mass., June 12, 2012 /PRNewswire/ -- Berg Pharma, a Boston-based pharmaceutical company presented at the 2012 American Society of Clinical Oncology meeting in Chicago on BPM 31510, the lead molecule in the Berg's cancer portfolio that targets the metabolism of cancer cells by reversing the Warburg phenotype. BPM 31510, an endogenous small molecule resident in mitochondria restores oxidative phosphorylation and confers re-capitulation of the BCL-2 protein family potential to...

2012-04-25 02:32:58

LONDON, April 25, 2012 /PRNewswire/ -- BT today announced that Berg Pharma and BT Global Services will be working together to accelerate the process of drug discovery and development, using resources and technology from both companies. The joint effort will focus on the use of innovative approaches to target identification and validation and on lead optimization of novel drug candidates. It will support the use of cloud-based high throughput molecular profiling techniques to select patients...

2012-04-04 14:22:30

CHICAGO, April 4, 2012 /PRNewswire/ -- Berg Pharma, a Boston based pharmaceutical company presented novel data today pertaining to key insights into cancer cell metabolism at the 103rd Annual AACR meeting. The company had a total of 5 presentations at the meeting that dealt with endothelial cell biology relative to tumor angiogenesis, mitochondrial flux in cancer cells for priming of cancer therapy, synergy of BPM 31510, Berg's lead oncology drug in development with gemcitabine, and use of...

2012-03-05 17:24:00

SAN FRANCISCO, March 5, 2012 /PRNewswire/ -- Berg Biosystems and Berg Diagnostics, members of the Berg Pharma group of companies based in Boston, MA presented "Novel Autism Spectrum Disorder (ASD) Biomarker Discovery Using the Berg Interrogative Biology® Discovery Platform" at US-HUPO meeting in San Francisco, CA. The study was conducted by assessing tissues from families with autistic children, and in some cases where more than 1 child was afflicted by the disorder. The presentations are...